Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för sonidegib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

12 träffar

Bibliografisk träff 2015-11-06

An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.

Danial C, Sarin KY, Oro AE, Chang AL.

Clin Cancer Res · clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1078-0432.ccr-15-1588

Bibliografisk träff 2015-10-29

Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model.

Roy Chaudhuri T, Straubinger NL, Pitoniak RF, Hylander BL, Repasky EA, Ma WW, Straubinger RM.

Mol Cancer Ther · research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-15-0602

Bibliografisk träff 2015-10-20

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.

Tibes R, Al-Kali A, Oliver GR, Delman DH, Hansen N, Bhagavatula K, Mohan J, Rakhshan F, Wood T, Foran JM, Mesa RA, Bogenberger JM.

J Hematol Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13045-015-0211-8

Bibliografisk träff 2015-06-08

Hedgehog Inhibitors in Rhabdomyosarcoma: A Comparison of Four Compounds and Responsiveness of Four Cell Lines.

Ridzewski R, Rettberg D, Dittmann K, Cuvelier N, Fulda S, Hahn H.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2015.00130

Bibliografisk träff 2015-05-14

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R.

Lancet Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(15)70100-2

Bibliografisk träff 2014-12-03

A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.

Shou Y, Robinson DM, Amakye DD, Rose KL, Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley DM, Hargrave DR, Casanova M, Tawbi HA, Rodon J, Thomas AL, Mita AC, MacDonald TJ, Kieran MW.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-13-1711

Bibliografisk träff 2014-08-05

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.

D'Amato C, Rosa R, Marciano R, D'Amato V, Formisano L, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fulciniti F, Cipolletta A, Bianco C, Ciardiello F, Veneziani BM, De Placido S, Bianco R.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/bjc.2014.421

Bibliografisk träff 2014-08-01

Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.

Steg AD, Burke MR, Amm HM, Katre AA, Dobbin ZC, Jeong DH, Landen CN.

Oncotarget · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.2295

Bibliografisk träff 2014-05-10

Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.

Zollinger M, Lozac'h F, Hurh E, Emotte C, Bauly H, Swart P.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-014-2468-y

Bibliografisk träff 2014-02-12

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC.

Clin Cancer Res · multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-13-1710

Bibliografisk träff 2013-07-30

NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.

Jalili A, Mertz KD, Romanov J, Wagner C, Kalthoff F, Stuetz A, Pathria G, Gschaider M, Stingl G, Wagner SN.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0069064

Bibliografisk träff 2013-03-12

NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200.

Fu J, Rodova M, Nanta R, Meeker D, Van Veldhuizen PJ, Srivastava RK, Shankar S.

Neuro Oncol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1093/neuonc/not011